Linked Life Data

17083508

Source:http://linkedlifedata.com/resource/pubmed/id/17083508

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
2006-11-6
pubmed:abstractText
The development of inhibitors to factor VIII is the most serious adverse event associated with the treatment of haemophilia A, predisposing patients to uncontrollable haemorrhage, disability and premature death. Eradication of inhibitors via immune tolerance induction (ITI) is effective in the majority of patients, but may require months to years to achieve success. In the interim, the treatment and prevention of acute bleeding episodes are primary foci of care. Regrettably, there is a paucity of information regarding management of bleeding episodes in inhibitor patients undergoing tolerization. Until specific data from ongoing clinical trials are available to provide more guidance in this patient group, it is reasonable and useful to rely on the broader base of medical literature pertaining to patients not being tolerized to deduce strategies for controlling acute and perioperative bleeding episodes in inhibitor patients during ITI.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Nov
pubmed:issn
1351-8216
pubmed:author
pubmed:issnType
Print
pubmed:volume
12
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
591-7
pubmed:dateRevised
2009-10-21
pubmed:meshHeading
pubmed:year
2006
pubmed:articleTitle
Application of current knowledge to the management of bleeding events during immune tolerance induction.
pubmed:affiliation
Department of Pediatrics, University of Iowa, Iowa City, IA 52242, USA. jorge-dipaola@uiowa.edu
pubmed:publicationType
Journal Article, Review